Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D03APM
|
|||
| Former ID |
DIB006858
|
|||
| Drug Name |
ABT-110
|
|||
| Synonyms |
Hu-alphaD11; PG-110; Humanized anti-NGF antibody (pain), Lay Line Genomics; Humanized anti-NGF antibody (pain), PanGenetics; Humanized anti-nerve growth factor antibody (pain), Lay Line Genomics; Humanized anti-nerve growth factor antibody (pain), PanGenetics
Click to Show/Hide
|
|||
| Indication | Chronic pain [ICD-11: MG30; ICD-10: R52.1, R52.2; ICD-9: 338.2, 780] | Phase 1 | [1] | |
| Company |
Abbvie
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00941746) Safety and Tolerability of PG110 in Patients With Knee Osteoarthritis Pain. U.S. National Institutes of Health. | |||
| REF 2 | Fate of novel painkiller mAbs hangs in balance.Nat Biotechnol.2011 Mar;29(3):173-4. | |||
| REF 3 | Targeting nerve growth factor (NGF) for pain management: what does the future hold for NGF antagonists Drugs.2014 Apr;74(6):619-26. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.